Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
A surge of hot, humid air
Doctors can stop providing life-support treatment to sick baby Charlie Gard, Court of Appeal judges have ruled.
Armed police officers are patrolling on board trains nationwide for the first time, British Transport Police has said.